899 W Evelyn Ave
150 articles with 23andMe
23andMe Successfully Closes its Business Combination with VG Acquisition Corp.Combined Company to Trade on Nasdaq Under Ticker “ME” Commencing June 17
23andMe, Inc., a leading consumer genetics and research company, and VG Acquisition Corp., a special purpose acquisition company sponsored by Virgin Group, announced the completion of their previously announced business combination.
Michael J. Fox Foundation and 23andMe Share New Genetic Data from the Largest Cohort in Parkinson's Research
Collaboration with 23andMe enables robust sharing of de-identified genetic data with researchers worldwide through the Fox Insight Data Exploration Network (Fox DEN)
Symptom most commonly observed in women and younger respondents, less commonly in those of East Asian and African American ancestry
Virgin Group's VG Acquisition Corp. Announces Date of Shareholders Meeting in Connection with its Pending Business Combination with 23andMe
VG Acquisition Corp., a special purpose acquisition company sponsored by Virgin Group, announced that the date of its extraordinary general meeting of shareholders to vote on its proposed business combination with 23andMe, Inc., a leading consumer genetics and research company, will be June 10, 2021.
With 2020 holding a record number of biotech IPOs, this year is lining up to come close. Three more Bay Area life science companies are just about ready to hit the Nasdaq, adding to the growing list for 2021.
2/10/2021The cash just keeps coming for biopharma companies. Here’s a rundown of some of this week’s investment dollar recipients.
Billionaire Sir Richard Branson believes in healthcare. This week he put more of his money where his mouth is by using his SPAC to take consumer DNA testing company 23andMe public in a massive deal.
23andMe to Merge with Virgin Group's VG Acquisition Corp. to Become Publicly-Traded Company Set to Revolutionize Personalized Healthcare and Therapeutic Development through Human Genetics
- 23andMe is a leading consumer genetics and research company that offers a personalized health and wellness experience, and has built a premier genetic database to unlock insights leading to the rapid discovery of promising new targets for drug development - Transaction will provide the capital to fund additional investment in key growth initiatives across 23andMe's consumer health and therapeutics businesses
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for Two Commonly Prescribed Medications
510(k) Clearance allows 23andMe to report interpretive drug information for medications prescribed for heart conditions and depression without the need for confirmatory testing
The layoffs are in departments across the company that aren’t central to its consumer testing and therapeutics business.
A competitor, Invitae Corporation, presented a poster at the American Society of Human Genetics (ASHG) annual meeting that essentially accuses 23andMe’s tests of completing missing a cancer-causing DNA variant in some ethnic groups.
23andMe Health + Ancestry Service Customer Survey Conducted by M/A/R/C Research: 76 Percent of Respondents Report Making a Positive Behavior Change After Getting 23andMe Results
Changes include diet, exercise, sleep and setting future health goals
23andMe and TrialSpark are announcing a joint clinical trial offering that combines the power of 23andMe's crowdsourced research platform and extensive database of consenting customers with TrialSpark's distributed site network and trial services.
March is National Women’s Month with March 8 specifically designated as International Women’s Day. Although this is not remotely a comprehensive list, BioSpace recognizes these 10 women (in no particular order) as being especially influential in the biopharma industry.
Personal genomics company 23andMe offers a new health predisposition report on type 2 diabetes, a condition predicted to affect 40 percent of Americans in their lifetime.
Lark's clinically validated AI coaching programs provide new ways for 23andMe customers to take action on their genetic information
When consumers have their genome tested by services like 23andMe and Ancestry.com, the companies hold the rights to the genetic information, which they often sell to biopharmaceutical companies. Nebula Genomics is taking a different approach.
Every year, Forbes creates a list of 30 Under 30, people under the age of 30 who have made a mark and show promise in various areas. They just came out with the 2019 30 Under 30: Healthcare. Here we highlight a dozen of the winners for their roles in biopharma-related endeavors.
The decision allows 23andMe to report directly to customers, without a prescription, the influence their genetics have on how well they metabolize certain medications
10/19/2018TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry.